JP2016501260A - マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−DS−Mal−IIIの使用 - Google Patents

マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−DS−Mal−IIIの使用 Download PDF

Info

Publication number
JP2016501260A
JP2016501260A JP2015546418A JP2015546418A JP2016501260A JP 2016501260 A JP2016501260 A JP 2016501260A JP 2015546418 A JP2015546418 A JP 2015546418A JP 2015546418 A JP2015546418 A JP 2015546418A JP 2016501260 A JP2016501260 A JP 2016501260A
Authority
JP
Japan
Prior art keywords
ppi
mal
dendrimer
iii
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015546418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501260A5 (cg-RX-API-DMAC10.html
Inventor
イダ・フラニアク−ピエトリガ
マリア・ブリシェフスカ
ディートマー・アッペルハンス
バルバラ・クライネルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Łódź
Original Assignee
University of Łódź
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Łódź filed Critical University of Łódź
Publication of JP2016501260A publication Critical patent/JP2016501260A/ja
Publication of JP2016501260A5 publication Critical patent/JP2016501260A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015546418A 2012-12-06 2013-12-03 マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−DS−Mal−IIIの使用 Pending JP2016501260A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLP.401934 2012-12-06
PL401934A PL234887B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PCT/PL2013/000154 WO2014088434A1 (en) 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii

Publications (2)

Publication Number Publication Date
JP2016501260A true JP2016501260A (ja) 2016-01-18
JP2016501260A5 JP2016501260A5 (cg-RX-API-DMAC10.html) 2017-01-19

Family

ID=49955471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015546418A Pending JP2016501260A (ja) 2012-12-06 2013-12-03 マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−DS−Mal−IIIの使用

Country Status (9)

Country Link
US (1) US20150320692A1 (cg-RX-API-DMAC10.html)
EP (1) EP2928478A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016501260A (cg-RX-API-DMAC10.html)
KR (1) KR20150099539A (cg-RX-API-DMAC10.html)
AU (1) AU2013356792A1 (cg-RX-API-DMAC10.html)
CA (1) CA2896673A1 (cg-RX-API-DMAC10.html)
IL (1) IL239143A0 (cg-RX-API-DMAC10.html)
PL (1) PL234887B1 (cg-RX-API-DMAC10.html)
WO (1) WO2014088434A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501261A (ja) * 2012-12-06 2016-01-18 ウニヴェルシテット・ウズキUniwersytet Lodzki マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−OS−Mal−IIIの使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501261A (ja) * 2012-12-06 2016-01-18 ウニヴェルシテット・ウズキUniwersytet Lodzki マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−OS−Mal−IIIの使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208580A1 (en) * 2005-09-19 2009-08-20 Regents Of The University Of Michigan Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
US20110177602A1 (en) * 2007-06-27 2011-07-21 Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG Composite Structure

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501261A (ja) * 2012-12-06 2016-01-18 ウニヴェルシテット・ウズキUniwersytet Lodzki マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−OS−Mal−IIIの使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. JANASZEWSKA, NEW JOURNAL OF CHEMISTRY, vol. V36 N2, JPN5016000505, 1 January 2012 (2012-01-01), pages 428 - 437, ISSN: 0003609146 *
BARBARA ZIEMBA, BIOPOLYMERS, vol. V97 N8, JPN5016000507, 17 August 2012 (2012-08-17), pages 642 - 648, ISSN: 0003609147 *
BARBARA ZIEMBA: "INFLUENCE OF FOURTH GENERATION POLY (PROPYLENEIMINE) DENDRIMERS ON BLOOD CELLS", JOURNAL OF BIOMEDICAL METERIALS RESEARCH PART A, vol. V100A N11, JPN5016000506, 24 November 2012 (2012-11-24), pages 2870 - 2880, ISSN: 0003753522 *
FRANIAK-PIETRYGA IDA, BLOOD, vol. V120 N21, JPN5016000504, 16 November 2012 (2012-11-16), pages 4601, ISSN: 0003609145 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501261A (ja) * 2012-12-06 2016-01-18 ウニヴェルシテット・ウズキUniwersytet Lodzki マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−OS−Mal−IIIの使用

Also Published As

Publication number Publication date
PL234887B1 (pl) 2020-04-30
EP2928478A1 (en) 2015-10-14
US20150320692A1 (en) 2015-11-12
KR20150099539A (ko) 2015-08-31
IL239143A0 (en) 2015-07-30
AU2013356792A1 (en) 2015-07-23
CA2896673A1 (en) 2014-06-12
PL401934A1 (pl) 2014-06-09
WO2014088434A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
Zhao et al. Sonodynamic therapy of NRP2 monoclonal antibody‐guided MOFs@ COF targeted disruption of mitochondrial and endoplasmic reticulum homeostasis to induce autophagy‐dependent ferroptosis
Nooshabadi et al. Impact of atorvastatin loaded exosome as an anti-glioblastoma carrier to induce apoptosis of U87 cancer cells in 3D culture model
Zeller et al. A novel phosphocholine‐mimetic inhibits a pro‐inflammatory conformational change in C‐reactive protein
US9861659B2 (en) Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof
He et al. Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells
Gravelle et al. Cell growth in aggregates determines gene expression, proliferation, survival, chemoresistance, and sensitivity to immune effectors in follicular lymphoma
CN111787945A (zh) 作为癌症免疫治疗的检查点阻断剂的工程化纳米囊泡
JP2023055865A (ja) ルテリアル、並びにその分離および培養方法
Mameri et al. Oxidative stress as an underlying mechanism of anticancer drugs cytotoxicity on human red blood cells' membrane
Pidala et al. Ixazomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium phase II trial
Albuz et al. Effects of B2O3 (boron trioxide) on colon cancer cells: our first-step experience and in vitro results
Ünsal et al. The apoptotic effect of garlic (Allium sativum) derived SEVs on different types of cancer cell lines in vitro
WO2020031136A1 (en) Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
US9877985B2 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III
US20150320692A1 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
US10022395B2 (en) Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III
EP3928792A1 (en) Peripheral blood biomarker for evaluating anti-tumor immune effect of radiation therapy
CN116785256A (zh) 一种可诱导细胞免疫性死亡的纳米颗粒材料及其制备方法和应用
Zhang et al. Caerulomycin A disrupts glucose metabolism and triggers ER stress-induced apoptosis in triple-negative breast cancer cells
Donmez et al. Investigation of the Effects of Three Different Generations of Fluoroquinolone Derivatives on Erythrocyte Fragility and Hematological Parameters in Rats
JP2004534001A (ja) 細胞に化学化合物を標的化する方法およびそれに使用する製薬学的組成物
Huang et al. Preparation and biocompatibility evaluation of PEG-PLL/RGD-PEG-DSPE/Phospholipid/CaP nanoparticles
RU2810558C1 (ru) Способ подбора лекарственных средств для реализации фармакологической индукции митохондриальной дисфункции в макрофагах для противоопухолевой терапии
WO2017163124A2 (en) Medical use of poly(propylene imine) glycodendrimers
Widodo et al. Immunohistochemical differential expression of p16 proteins in follicular type and plexiform type ameloblastoma

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180313